A U.K. Court of Appeals ruling confirms the validity of a patent covering modifications of mRNA used in Moderna’s vaccines.

The biotechnology company on Friday said the U.K. Court of Appeal upheld the validity of its EP'949 patent. It noted the decision affirms the court's initial ruling from July 2024 that the patent is ...

Massachusetts-based Moderna said it plans to cut 10% of its global staff as part of its ongoing efforts to reduce annual ...

Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal has upheld the validity of Moderna's EP'949 patent.

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

London's Court of Appeal on Friday struck down a case filed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX), in a bid to ...

Pfizer says it will appeal the Aug 1 ruling to Britain’s Supreme Court. Read more at straitstimes.com. Read more at ...

Despite efforts to spare employees by scaling back R&D and reducing operating costs by roughly $1.5 billion over the next two ...

Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed ...

The U.S. Food and Drug Administration approved Pfizer and Moderna's updated COVID-19 vaccines amid a summer surge and ahead of an expected winter spike.

So far, studies have shown that mRNA vaccines -- those made by Pfizer and Moderna -- maintain more than 90% efficacy six months after getting vaccinated. And scientists say it's likely much longer.